High Dose Pulsatile Dexamethasone Therapy in Children with Opsoclonus-Myoclonus Syndrome

Abstract

Opsoclonus-myoclonus syndrome (OMS) is a rare movement disorder characterized by chaotic eye movements, myoclonus, and ataxia associated with severe irritability. Different treatment modalities including steroids and cyclophosphamide have been tried in the past often with significant side effects and variable success. Here we present 11 children, diagnosed with OMS between 1999 and 2005 and treated with high dose dexamethasone pulses. Main symptoms at presentation were opsoclonus (11/11), ataxia and/or myoclonus (11/11), irritability (10/11) associated with a neuroblastoma in four children. Number of dexamethasone pulses ranged from 6 to 60 pulses. No major side effects were reported. In 6/11 children a complete and sustained remission of OMS symptoms was achieved after 6 to 29 pulses of dexamethasone. Two children from this group have a normal development and no neurological sequelae. Two further children have minor delays in fine- and gross-motor skills. Two children despite a complete recovery of OMS symptoms have persisting developmental problems. 5/11 children still require regular dexamethasone pulses in addition to daily prednisolone (n = 1) or have received cyclophosphamide pulses meanwhile (n = 2). All children continue to have developmental and neurological difficulties. In summary treatment with high dose pulsatile dexamethasone appears to be safe and beneficial in a subgroup of patients with OMS.

Children - opsoclonus-myoclonus syndrome - dexamethasone - therapy

References

• 1 Antunes N L, Khakoo Y, Matthay K K, Seeger R C, Stram D O, Gerstner E. et al . Antineuronal antibodies in patients with neuroblastoma and paraneoplastic opsoclonus-myoclonus.  J Pediatr Hematol Oncol. 2000;  22 315-320
• 2 Blaes F, Fühlhuber V, Korfei M, Tschernatsch M, Behnisch W, Rostásy K, Hero B, Kaps M. Surface-binding autoantibodies to cerebellar granular neurons in childhood opsoclonus-myoclonus syndrome.  Ann Neurol. 2005;  58 313-317
• 3 Connolly A M, Pestronk A, Mehta S, Pranzatelli M R, Noetzel M J. Serum autoantibodies in childhood opsoclonus-myoclonus syndrome: an analysis of antigenic targets in neural tissues.  Journal of Pediatrics. 1997;  130 878-884
• 4 Di Giannuario A, Pieretti S, Sagratella S, Loizzo A. Dexamethasone blocking effects on mu- and delta opoid-induced seizures involves kappa-opoid activity in the rabbit.  Neuropsychobiology. 2001;  43 213-220
• 5 Karenfurt M, Wilken B, Hanefeld F. Pulsatile dexamethasone pulse therapy in symptomatic infantile spasm.  Neuropediatrics. 2002;  33 A52
• 6 Matthay K K, Blaes F, Hero B, Plantaz D, De Alarcon, Mitchell W G, Pike M, Pistoia V. Opsoclonus myoclonus syndrome in neuroblastoma: a report from a workshop on the dancing eye syndrome at the advances in neuroblastoma meeting in Genoa, Italy, 2004.  Cancer Letters. 2005;  228 275-282
• 7 Mitchell W G, Davalos-Gonzalez Y, Brumm V L, Aller S K, Burger E, Turkel S B, Borchert M S, Hollar S, Padilla S. Opsoclonus-ataxia caused by childhood neuroblastoma: developmental and neurologic sequelae.  Pediatrics. 2002;  109 86-98
• 8 Plantaz D, Michon J, Valteau-Couanet D, Coze C, Chastagner P, Bergeron C. et al . Opsoclonus-myoclonus syndrome associated with non-metastatic neuroblastoma. Long-term survival. Study of the French Society of Pediatric Oncologist.  Arch Pediatr. 2000;  7 621-628
• 9 Pohl K R, Pritchard J, Wilson J. Neurological sequelae of the dancing eye syndrom.  Eur J Pediatr. 1996;  155 237-244
• 10 Pranzatelli M R, Tate E D, Kinsbourne M, Caviness Jr V S, Mishra B. Forty-one year follow-up of childhood-onset opsoclonus-myoclonus-ataxia: Cerebellar atrophy, multiphasic relapses, and response to IVIG.  Mov Disord. 2002;  17 1387-1390
• 11 Pranzatelli M R, Travelstead A L, Tate E D, Allison T J, Verhulst C SF. B-cell expansion in opsoclonus-myoclonus syndrome: a biomarker of disease activity.  Mov Disorder. 2004;  19 770-777
• 12 Pranzatelli M R, Tate E D, Travelstead A L, Longee D. Immunologic and clinical responses to rituximab in a child with opsoclonus-myoclonus syndrome.  Pediatrics. 2005;  115 115-119
• 13 Rudnick E, Khakoo Y, Antunes N L, Seeger R C, Brodeur G M, Shimada H. et al . Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma: clinical outcome and antineuronal antibodies - a report from the Children's Cancer Group Study.  Med Pediatr Oncol. 2001;  36 612-622
• 14 Russo C, Cohn S L, Petruzzi M J, de Alarcon P A. Long-term neurologic outcome in children with opsoclonus-myoclonus associated with neuroblastoma: a report from the Pediatric Oncology Group.  Medical & Pediatric Oncology. 1997;  28 284-288
• 15 Sloka J S, Stefanelli M. The mechanism of action of methyprednisolone in the treatment of multiple sclerosis.  Multiple Sclerosis. 2005;  11 425-432
• 16 Veneselli E, Conte M, Biancheri R, Acquaviva A, De Bernardi B. Effect of steroid and high-dose immunoglobulin therapy on opsoclonus-myoclonus syndrome occurring in neuroblastoma.  Medical & Pediatric Oncology. 1998;  30 15-17